Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

NCT04818398 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG: DS-6016a
DRUG: Placebo

Sponsor

Daiichi Sankyo Co., Ltd.